511 related articles for article (PubMed ID: 29922758)
1. 100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
Iacob S; Cerban R; Pietrareanu C; Ester C; Iacob R; Gheorghe C; Popescu I; Gheorghe L
J Gastrointestin Liver Dis; 2018 Jun; 27(2):139-144. PubMed ID: 29922758
[TBL] [Abstract][Full Text] [Related]
2. Ledipasvir/sofosbuvir; ombitasvir/paritaprevir/ritonavir/dasabuvir sodium monohydrate; and peramivir.
Hussar DA; Kavelak HL
J Am Pharm Assoc (2003); 2015; 55(2):216, 219-20, 222. PubMed ID: 25749267
[No Abstract] [Full Text] [Related]
3. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.
Chen CH; Chen CH; Lin CL; Lin CY; Hu TH; Tung SY; Hsieh SY; Lu SN; Chien RN; Hung CH; Sheen IS
Sci Rep; 2019 May; 9(1):7086. PubMed ID: 31068655
[TBL] [Abstract][Full Text] [Related]
4. Real-Life Use of 3 Direct-Acting Antiviral Regimen in a Large Cohort of Patients with Genotype-1b HCV Compensated Cirrhosis.
Gheorghe L; Iacob S; Curescu M; Brisc C; Cijevschi C; Caruntu F; Stanciu C; Simionov I; Sporea I; Gheorghe C; Iacob R; Arama V; Sirli R; Trifan A
J Gastrointestin Liver Dis; 2017 Sep; 26(3):275-281. PubMed ID: 28922440
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
Pessoa MG; Ramalho-Madruga JV; Alves K; Nunes EP; Cheinquer H; Brandão-Mello CE; Mendes-Correa MC; Ferraz ML; Ferreira PRA; Álvares-da-Silva MR; Coelho HS; Affonso-de-Araújo ES; Furtado J; Parana R; Silva G; Lari SA; Liu L; Tripathi R; Pilot-Matias T; Cohen DE; Shulman NS; Martinelli A
Ann Hepatol; 2018 Oct; 17(6):959-968. PubMed ID: 30600291
[TBL] [Abstract][Full Text] [Related]
6. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
Tronina O; Durlik M; Wawrzynowicz-Syczewska M; Buivydiene A; Katzarov K; Kupcinskas L; Tolmane I; Karpińska E; Pisula A; Karwowska KM; Bolewska B; Jabłkowski M; Rostkowska K; Jakutiene J; Simonova M; Flisiak R
Ann Transplant; 2017 Apr; 22():199-207. PubMed ID: 28386057
[TBL] [Abstract][Full Text] [Related]
7. Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
Isakov V; Paduta D; Viani RM; Enejosa JV; Pasechnikov V; Znoyko O; Ogurtsov P; Bogomolov PO; Maevskaya MV; Chen X; Shulman NS
Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1073-1076. PubMed ID: 29762255
[TBL] [Abstract][Full Text] [Related]
8. Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.
Steiner S; Bucsics T; Schwabl P; Mandorfer M; Scheiner B; Aichelburg MC; Grabmeier-Pfistershammer K; Ferenci P; Trauner M; Peck-Radosavljevic M; Reiberger T
Wien Klin Wochenschr; 2017 Aug; 129(15-16):517-526. PubMed ID: 28130599
[TBL] [Abstract][Full Text] [Related]
9. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience.
Yu ML; Chen YL; Huang CF; Lin KH; Yeh ML; Huang CI; Hsieh MH; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL
J Formos Med Assoc; 2018 Jun; 117(6):518-526. PubMed ID: 28662883
[TBL] [Abstract][Full Text] [Related]
10. Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients.
Özer Etik D; Suna N; Öcal S; Selçuk H; Dağlı Ü; Çolak T; Hilmioğlu F; Boyacıoğlu AS; Haberal M
Exp Clin Transplant; 2019 Feb; 17(1):52-58. PubMed ID: 30719954
[TBL] [Abstract][Full Text] [Related]
11. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Petta S; Marzioni M; Russo P; Aghemo A; Alberti A; Ascione A; Antinori A; Bruno R; Bruno S; Chirianni A; Gaeta GB; Giannini EG; Merli M; Messina V; Montilla S; Perno CF; Puoti M; Raimondo G; Rendina M; Silberstein FC; Villa E; Zignego AL; Pani L; Craxì A; ;
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):427-434. PubMed ID: 28497758
[TBL] [Abstract][Full Text] [Related]
12. Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.
Khatri A; Mensing S; Podsadecki T; Awni W; Menon R; Dutta S
Clin Drug Investig; 2016 Aug; 36(8):625-35. PubMed ID: 27153823
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study.
Janczewska E; Zarębska-Michaluk D; Berak H; Piekarska A; Gietka A; Dybowska D; Mazur W; Belica-Wdowik T; Dobracki W; Tudrujek-Zdunek M; Deroń Z; Buczyńska I; Sitko M; Czauż-Andrzejuk A; Lorenc B; Białkowska-Warzecha J; Citko J; Laurans Ł; Jaroszewicz J; Socha Ł; Tronina O; Adamek B; Horban A; Halota W; Baka-Ćwierz B; Tomasiewicz K; Simon K; Garlicki A; Wawrzynowicz-Syczewska M; Flisiak R
BMC Infect Dis; 2018 Nov; 18(1):580. PubMed ID: 30445916
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
15. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Bailly F; Pradat P; Virlogeux V; Zoulim F
Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
[TBL] [Abstract][Full Text] [Related]
16. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
Andreone P; Colombo MG; Enejosa JV; Koksal I; Ferenci P; Maieron A; Müllhaupt B; Horsmans Y; Weiland O; Reesink HW; Rodrigues L; Hu YB; Podsadecki T; Bernstein B
Gastroenterology; 2014 Aug; 147(2):359-365.e1. PubMed ID: 24818763
[TBL] [Abstract][Full Text] [Related]
17. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
Feld JJ; Moreno C; Trinh R; Tam E; Bourgeois S; Horsmans Y; Elkhashab M; Bernstein DE; Younes Z; Reindollar RW; Larsen L; Fu B; Howieson K; Polepally AR; Pangerl A; Shulman NS; Poordad F
J Hepatol; 2016 Feb; 64(2):301-307. PubMed ID: 26476290
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
Lawitz E; Makara M; Akarca US; Thuluvath PJ; Preotescu LL; Varunok P; Morillas RM; Hall C; Mobashery N; Redman R; Pilot-Matias T; Vilchez RA; Hézode C
Gastroenterology; 2015 Oct; 149(4):971-80.e1. PubMed ID: 26170136
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study.
Butt AA; Ren Y; Puenpatom A; Arduino JM; Kumar R; Abou-Samra AB
Aliment Pharmacol Ther; 2018 Jul; 48(1):35-43. PubMed ID: 29797514
[TBL] [Abstract][Full Text] [Related]
20. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
Feld JJ; Kowdley KV; Coakley E; Sigal S; Nelson DR; Crawford D; Weiland O; Aguilar H; Xiong J; Pilot-Matias T; DaSilva-Tillmann B; Larsen L; Podsadecki T; Bernstein B
N Engl J Med; 2014 Apr; 370(17):1594-603. PubMed ID: 24720703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]